Aimmune Therapeutics (AIMT) Tops Q1 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Burry doubles down on Nebius short after stock surges 34% on earnings
- Total darkness, then sunset as full eclipse wows spectators in Spain
Aimmune Therapeutics (AIMT) Has a Catalyst Filled Second Half - Piper Jaffray
May 17, 2016 9:11 AM EDTPiper Jaffray Aimmune Therapeutics (NASDAQ: AIMT) analyst, Charles Duncan, believes that investigator and patient interest remains high at PALISADE trial sites and that enrollment is on track to complete in 2H16. The company is currently focused on EU site initiations, as it plans... More
